[Drug protection of the myocardium during cardiac surgery].
During aortic clamping, drug protection of the myocardium, far from supplanting hypothermia, complements it, particularly in the case of left ventricular hypertrophy. Ultramicroscopy and new techniques of histobiological exploration of the myocite have enabled one to distinguish the lessions provoked by anoxia from those induced by reperfusion. At present, drug protection, extended to energetic solutions and electrolytes, aim at preserving energy metabolism by stocking of the substrate and at avoiding interferences which precipitate exhaustion of the adenosine triphosphate and phosphocreatinine reserves. In order to do this, hemodilution in particular is limited in subjects with decompensated cardiopathy; choice of anesthetics is orientated towards neuroleptanalgesia or fluothane, and it is attempted to neutralize the adrenergic reaction by the use of beta-blocking substances. Furthermore, it is preferred to interrupt electrogenesis at the stage of polarization: depolarizing cardioplegic solutions rich in potassium and sodium are rejected and in preference membrane stabilizers are used (procaine, magnesium, tetrodoxine...) The ultramicroscopic analysis of the structural modifications leads to sparing of the integrity of the lysosomial membrane by corticoids and alkalines. The use of calcium is deferred, anti-calcium techniques are even proposed (washing poor in calcium, verapamil). Cellular edema is prevented and treated by solution (mannitol - sorbitol) whose osmolarity must be less than 300 M osm/l. A conditioning of the biochemical and physicial structures and of cardiac work is being more and more thought of which leads to the classification of beta stimulating substances as negative, and their indications must be seriously thought of and used with reserve.
D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000758:Anesthesia / Q000009:adverse effects*; D006348:Cardiac Surgical Procedures / Q000379:methods*; D003326:Coronary Circulation / Q000187:drug effects*; D003402:Creatine Kinase / Q000627:therapeutic use; D004487:Edema / Q000517:prevention & control; D005112:Extracorporeal Circulation / Q000379:methods*; D005947:Glucose / Q000627:therapeutic use; D006221:Halothane; D006324:Heart Arrest, Induced; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008247:Lysosomes; D009200:Myocardial Contraction; D009458:Neuroleptanalgesia; D010101:Oxygen Consumption; D010952:Plasma Substitutes; D011183:Postoperative Complications / Q000517:prevention & control
D000319:Adrenergic beta-Antagonists; D010952:Plasma Substitutes; D000255:Adenosine Triphosphate; D003402:Creatine Kinase; D005947:Glucose; D006221:Halothane
Protection médicamenteuse du myocarde au cours de la chirurgie cardiaque